Have followed DXB since prior to phase 2's and held from...

Have followed DXB since prior to phase 2's and held from 0.10-0.70's. Re-entered recently based on compelling value for such a late stage asset. I dislike hyperbole but subject to a successful phase 3 this has the potential of being a $3bn MC company - that equates to > 100 bhags from here.

Needless to say it will either “expire worthless” or deliver a “multi-bagger” depending on the science.
For context (in response to your (mis)representation, I followed NEU for a decade and increased at 2.4 on the phase 3 readout for 600%. Was also buying around the $1 mark which is perhaps the equivalent to where DXB is news void wise (albeit NEU multi bagger potential was somewhat limited based on being in excess of $100m mc then).
I've found both DXB and NEU have credible management teams and both are predominantly ex Acrux and left after it's sale to work for NEU and DXB respectively.
DXB seems attractive value here; noting biotech investing is all about timing.